Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Health Tech·Hinge Health

Hinge Health tops its own forecast with 52% growth and raises its 2026 outlook again

Third-quarter revenue of $235 million beat the $223 million to $225 million Hinge Health had forecast in August, and the company lifted full-year revenue guidance to $879 million to $881 million.

From Hinge Health's third-quarter earnings release, filed with the SEC Nov. 2, 2026, and its second-quarter release for prior guidance
Two Hinge Health executives in front of the company's logo, in a photo from its media kit.
Two Hinge Health executives in front of the company's logo, in a photo from its media kit.Courtesy of Hinge Health

In August, Hinge Health told investors to expect third-quarter revenue of $223 million to $225 million. It brought in $235 million.

The San Francisco company said Nov. 2 that revenue rose 52% from $154.2 million a year earlier and that it earned $57.4 million, or 66 cents a diluted share, compared with a net loss of $1.8 million. It also raised its full-year forecasts for revenue and operating profit, as it had in August.

Why it matters: Hinge is adding revenue at a 52% clip while widening its margins. Non-GAAP income from operations, the profit measure it uses in guidance, rose 154% to $77.2 million, above the $61 million to $63 million it had forecast, for a 33% margin compared with 20% a year earlier.

The results stood apart from those of Teladoc Health, which reported days earlier that third-quarter revenue fell 3% as cash-pay revenue at its BetterHelp therapy unit declined.

Clients, programs and cash

Hinge said it had 3,270 clients at the end of September, up 28% from 2,560 a year earlier. Calculated billings over the trailing 12 months rose 54% to $960.3 million from $624.2 million.

Daniel Perez, co-founder and chief executive, said the company's approach is "resulting in a record sales season." He said the client base for its musculoskeletal program is up almost 30% from a year earlier and that the migraine program's client base has nearly doubled since the prior quarter. The client base for its gastrointestinal program has grown roughly 40% since Hinge announced its deal for Cylinder Health in August, Perez said, and the company expects to launch an integrated gastrointestinal care program in 2027.

GAAP gross margin widened to 87% from 82%, and GAAP income from operations was $50.3 million, compared with a $6.1 million operating loss a year earlier. Operating cash flow was $114.6 million and free cash flow was $112.7 million, up from $81.3 million, which the company put at a 48% margin. Hinge ended the quarter with $358.5 million in cash, cash equivalents, marketable securities and restricted cash.

Guidance raised

Hinge now expects 2026 revenue of $879 million to $881 million, up from $856 million to $860 million in August, which it said would mean 50% growth at the midpoint. It raised its forecast for non-GAAP income from operations to $266 million to $268 million from $236 million to $244 million, a 30% margin at the midpoint.

For the fourth quarter, Hinge forecast revenue of $249 million to $251 million, or 46% growth at the midpoint, and non-GAAP income from operations of $81 million to $83 million.

For the first nine months of 2026, revenue was $630.1 million and net income $136.2 million. In the same period of 2025, Hinge posted a net loss of $560.4 million.

What comes next

Jim Pursley will leave the president's post on Jan. 1, 2027, and join the board on Jan. 4, the company said. Aaryn Pure will then become chief commercial officer, running the commercial organization. Perez credited Pursley with helping the company scale to more than 3,200 clients.

Hinge plans its gastrointestinal launch in 2027, the year Pure takes over the commercial organization.

Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Health Tech

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.